BRIEF-Achillion Pharmaceuticals to support a natural history study of C3 glomerulopathy
February 28, 2017 at 06:32 AM EST
* Achillion Pharmaceuticals to support a natural history study of C3 glomerulopathy, a rare renal disorder, conducted by experts at Imperial College London Source text for Eikon: Further company coverage:
